Fluoroquinolone resistance in members of the Enterobacteriaceae family is mostly due to mutations in the quinolone resistance-determining regions of the topoisomerase genes. However, transferable genes encoding quinolone resistance have recently been described. The current methods for susceptibility testing are not adapted to the detection of new resistance determinants, which confer low levels of resistance. The aim of this study was to compare the ability of the screening of the different quinolones by disk diffusion assays and MIC determinations to detect fluoroquinolone resistance. Sixty-nine Escherichia coli strains and 62 Salmonella strains, including strains fully susceptible to quinolones, nalidixic acid-resistant strains, strains with resistance to fluoroquinolones (resistant to nalidixic acid), and strains showing low-level resistance to fluoroquinolones conferred by transferable quinolone resistance genes, including qnrA, qnrB, qnrS, and aac(6)Ib-cr, were selected. Disk diffusion assays and MIC determinations by the agar dilution method were performed, according to CLSI standards, with nalidixic acid, flumequine, oxolinic acid, ciprofloxacin, enrofloxacin, marbofloxacin, norfloxacin, ofloxacin, and levofloxacin. The MIC of levofloxacin was determined by an Etest. The results showed a trimodal distribution of the MICs for both E. coli and Salmonella. The MIC distributions for the isolates varied with the compounds tested. Screening for nalidixic acid resistance by MIC testing or disk diffusion assay was not efficient for the detection of some of the isolates carrying qnr and aac(6)Ib-cr. Transferable resistance genes would best be detected by testing for the MIC of ciprofloxacin or norfloxacin, as testing for the MICs of the other compounds would fail to detect isolates carrying aac(6)Ib-cr because the enzyme produced is able to reduce the activities of these two compounds only due to their chemical structures.
Fluoroquinolone resistance in members of the Enterobacteriaceae family has until recently been attributed to mutations in the gyrase and topoisomerase genes quinolone resistance-determining regions (QRDRs). Stepwise increases in resistance have been described for both Escherichia coli and Salmonella enterica species as a result of the accumulation of topoisomerase mutations (14) . Efflux pump mechanisms were also described to act in resistance alone or in combination with decreased levels of expression of outer membrane porins (20, 21, 27) . However, in the late 1990s, Martinez-Martinez et al. found a new plasmid-mediated mechanism, qnrA1, that is able to increase the MICs of quinolones through a target protection mechanism (18) . Other related qnr genes (qnrA, qnrB, qnrC, and qnrS) and numerous variants have been described (13, 15, 16) . Furthermore, a new resistance mechanism, aac(6Ј)Ib-cr, based on the enzymatic modification of some fluoroquinolones was described (23) . However, the reduction in the susceptibility to fluoroquinolones might not be observed when other quinolones, such as enrofloxacin, pefloxacin, gemifloxacin, and levofloxacin, are tested (22, 23) .
The actual screening methods include nalidixic acid as the first screening drug, since the sensitivity of the MIC test is higher for the detection of first-step mutants. However, the use of nalidixic acid might not be appropriate for the detection of these recently described resistance determinants that do not affect the MIC of nalidixic acid in the same way that mutations in the QRDRs of topoisomerases do. Furthermore, the breakpoints for quinolones for the detection of reduced susceptibility in surveillance programs have been under discussion to improve the detection of resistance determinants (5, 7) .
The methods for the detection of recently described transferable resistance are not well established, and if susceptibility testing is performed according to the CLSI guidelines and interpretations (8, 9, 10) , the isolates carrying these resistant mechanisms would be classified as susceptible since they me-diate a reduction in susceptibility which is below the actual clinical breakpoints, although their clinical importance is still unclear.
Given their transferability and the possibility that they cause increases in resistance that might affect the clinical response to treatment, the detection of quinolone resistance should routinely be performed. Therefore, laboratories will have to adapt the detection methods that they use. The detection of quinolone resistance might be facilitated through the selection of the drugs that are the most adequate for use in susceptibility tests and by the recognition of the expected phenotypes, isolates with which can then be further studied for their genetic backgrounds.
As part of this study, we measured the MICs and inhibition zone diameters for a panel of quinolones used in human and veterinary medicine to observe the distribution of quinolonesusceptible isolates and isolates harboring different mechanisms of resistance. This information could be useful for the optimization of quinolone resistance detection and the establishment of cutoff values and the interpretative criteria to be used for the detection of quinolone resistance for clinical and surveillance purposes.
MATERIALS AND METHODS
Bacterial isolates. Our strain collection comprised two subsets consisting of 69 Escherichia coli isolates and 62 Salmonella isolates. Each of these subsets included susceptible isolates; well-characterized nalidixic-acid resistant strains with one mutation in the QRDRs of the topoisomerase genes; and low-level-resistant strains with either qnrA, qnrB, or qnrS and aac(6Ј)Ib-cr. The strains either were from our collections or were previously described in the literature, and they were obtained from the respective authors and included in the assays as controls (Table 1) .
Antimicrobial substance. The antimicrobial substances used in the assays were obtained either as powder for the dilution assays or as disks for the disk diffusion assays, as described in Table 2 .
MIC testing. MIC determinations were performed according to the standards of the CLSI (8, 10) by agar dilution assays for nalidixic acid, flumequine, oxolinic acid, ciprofloxacin, enrofloxacin, marbofloxacin, norfloxacin, and ofloxacin. Susceptibility to levofloxacin was determined by Etest (AB Biodisk, Solna, Sweden). Quality control was performed for every determination by testing Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, and Pseudomonas aeruginosa ATCC 27853.
Disk diffusion testing. Antimicrobial susceptibility testing by disk diffusion was performed according to the standards of the CLSI (8, 9) for nalidixic acid, flumequine, oxolinic acid, ciprofloxacin, enrofloxacin, marbofloxacin, norfloxacin, ofloxacin, and levofloxacin. Quality control was performed in parallel by testing E. coli ATCC 25922.
RESULTS
In general, the results of the MIC determinations and the disk diffusion assays gave a trimodal distribution with distinct susceptible and resistant isolates, as well as isolates in between with reduced susceptibility. The distributions of the intermediate resistance levels varied, depending on the resistance mechanism present (a single gyrA mutation or the presence of transferable quinolone resistance-conferring genes) and the drug tested (Tables 3 to 6) .
Determination of MIC and disk diffusion assay results with nalidixic acid (30-g disks). Determination of the MIC for nalidixic acid allowed the clear separation of susceptible isolates and those carrying one mutation or multiple mutations in the QRDRs of the topoisomerase genes (MICs Ն 32 mg/ liter). However, screening with this drug did not allow the detection of all isolates carrying transferable resistance determinants.
The results of the nalidixic acid disk diffusion assay allowed the good separation of the wild-type isolates and those containing mutations in the QRDRs of the topoisomerase genes but not the strains carrying transferable resistance genes.
Determination of MIC and disk diffusion assay results with flumequine (30-g disks).
Determination of the MIC for The results of the flumequine disk diffusion assay allowed the good separation of wild-type isolates and those containing qnr genes or mutations in the QRDRs of topoisomerase genes; however, as for the MIC determination, it did include the E. coli isolate carrying aac(6Ј)Ib-cr (inhibition zone diameter, 31 mm) in the susceptible population.
Determination of MIC and disk diffusion assay results with oxolinic acid (2-g disks). Determination of the MIC for oxolinic acid allowed the clear separation of the susceptible E. coli and Salmonella isolates (MICs, Յ0.5 mg/liter and Յ0.25 mg/ liter, respectively) from those carrying qnr genes or mutations in the QRDRs of the topoisomerase genes, but it did not allow the detection of the E. coli strain harboring aac(6Ј)Ib-cr (MIC ϭ 0.25 mg/liter).
The results of the oxolinic acid disk diffusion assay allowed the good separation of the wild-type isolates and those containing qnr or mutations in the QRDRs of the topoisomerase genes; however, the E. coli isolate carrying aac(6Ј)Ib-cr and a Salmonella isolate carrying qnr were classified in the group of susceptible isolates.
Determination of MIC and disk diffusion assay results with ciprofloxacin (1-and 5-g disks) . Determination of the MIC for ciprofloxacin allowed the separation of the susceptible isolates and most isolates carrying mutations in the QRDRs of the topoisomerase genes by use of EUCAST cutoff values of 0.06 mg/liter for E. coli and 0.12 mg/liter for Salmonella. However, the MIC determination did not allow the separation of one E. coli strain with a first mutation in the gyrA gene and another strain containing aac(6Ј)Ib-cr (MIC ϭ 
org/).
The results of the disk diffusion assay with the 5-g disks showed a slight overlap of the inhibition zone diameters between the wild-type isolates and those containing resistance mechanisms, whereas the results of the disk diffusion assay with the 1-g disks showed a better separation of the population of wild-type isolates and isolates containing one or more mutations in the QRDRs of the topoisomerase genes. As described above, the disk diffusion assay with ciprofloxacin and disks with the low concentration allowed the detection of isolates carrying aac(6Ј)Ib-cr.
Determination of MIC and disk diffusion assay results with norfloxacin (10 g disks).
Determination of the MIC for norfloxacin allowed the separation of wild-type isolates and those carrying mutations in the QRDRs of the topoisomerase genes or a transferable resistance gene (MICs Ն 0.25 mg/liter).
The results of the disk diffusion assay showed a slight overlap of the inhibition zone diameters between the wildtype isolates and those containing one or more mutations in the QRDRs of the topoisomerase genes among the Salmonella isolates; however, any of the transferable resistance genes could be detected by using a low breakpoint (inhibition zone diameters, Յ32 mm).
Determination of MIC and disk diffusion assay results with enrofloxacin (5-g disks).
Determination of the MIC for enrofloxacin allowed the clear separation of the susceptible isolates and those carrying one or multiple mutations in the QRDRs of the topoisomerase genes and qnr genes (MICs, Ն0.125 for E. coli and 0.25 mg/liter) for Salmonella. However, the MIC determination did not to allow the isolates carrying aac(6Ј)Ib-cr to be distinguished from the susceptible isolates.
The results of the disk diffusion assay showed the good separation of the inhibition zone diameters between the wildtype isolates (Ն29 mm) and those containing mutations in the QRDRs of the topoisomerase genes or transferable resistance genes (Յ28 mm); however, the E. coli isolate carrying aac(6Ј)Ib-cr (inhibition zone diameter, 33 mm) would be grouped with the wild-type strains and therefore would not be detected.
Determination of MIC and disk diffusion assay results with marbofloxacin (5-g disks).
Determination of the MIC for marbofloxacin allowed the clear separation of the susceptible isolates and those carrying one or multiple mutations in the QRDRs of the topoisomerase genes for both species or in the qnr genes (MICs Ն 0.125 mg/liter). However, the MIC determination did not separate the E. coli isolate containing aac(6Ј)Ib-cr (MIC ϭ 0.03 mg/liter) from the susceptible isolates.
The results of the disk diffusion assay showed the separation of the inhibition zone diameters of the wild-type isolates and those containing one or more mutations in the QRDRs of the topoisomerase genes of E. coli or Salmonella (inhibition zone diameters, Յ33 and 32 mm, respectively); however, both isolates carrying aac(6Ј)Ib-cr would be grouped with the wild-type strains and therefore would not be detected.
Determination of MIC and disk diffusion with ofloxacin (5-g disks).
Determination of the MIC for ofloxacin allowed the clear separation of the susceptible isolates and those carrying one or multiple mutations in the QRDRs of the topoisomerase genes or qnr genes (MICs Ն 0.25 mg/liter). However, the MIC determination did not separate the E. coli isolate carrying aac(6Ј)Ib-cr (MIC ϭ 0.06 mg/liter) from the susceptible isolates.
The results of the disk diffusion assay showed the good separation of the inhibition zone diameters of the wild-type isolates (Ն30) and those containing one or more mutations in the QRDRs of the topoisomerase genes (Յ29 mm) in both species; however, neither isolate carrying aac(6Ј)Ib-cr (inhibition zone diameters, 32 and 33 mm for E. coli and Salmonella isolates, respectively) could be distinguished from the wild-type isolates.
Determination of MIC and disk diffusion assay results with levofloxacin (5-g disks).
Determination of the MIC for levofloxacin by Etest allowed the clear separation of the susceptible isolates and those carrying one or multiple mutations in the The results of the disk diffusion assay showed some overlap of the inhibition zone diameters between the E. coli wild-type isolates and isolates containing one or more mutations in the QRDRs of the topoisomerase genes. Furthermore, both E. coli and Salmonella isolates carrying aac(6Ј)Ib-cr (inhibition zone diameters, 35 and 33 mm, respectively) would be grouped with the wild-type strains and therefore would not be detected.
DISCUSSION
The emergence of new mechanisms of quinolone resistance, namely, those caused by the horizontal transfer of resistance genes on mobile genetic elements, are of great concern since they bring new possibilities for the spread of resistance. However, the phenotypes resulting from quinolone resistance caused by topoisomerase gene mutations or by these transferable resistance determinants are diverse, increasing the difficulty of the detection of resistance.
The interpretation of susceptibility testing results has mostly been based on clinical breakpoints, which have been used to predict treatment success or failure; however, these breakpoints have been set by the use of data for strains harboring mutations in the QRDR of the topoisomerase genes and have not yet been adapted to the presence of transferable resistance determinants. These resistance determinants might have an influence on the outcome of treatment because of either the reduction in the level of susceptibility that they cause or an additive effect on the resistance levels conferred by additional topoisomerase gene mutations, which might lead to higher levels of resistance. The use of the epidemiological cutoffs set by EUCAST (www.eucast.org) and the separation of wild-type isolates from those that display resistance mechanisms have recently been adopted by many laboratories, mostly for monitoring purposes. The use of these methods provides a higher sensitivity for the detection of resistance mechanisms.
However, regarding the new mechanisms of resistance to quinolones, the resistance levels that have been observed are the result of acquired resistance genes and vary for the different quinolones, as described previously for isolates carrying qnr, aac(6Ј)Ib-cr, and qepA genes (22) (23) (24) 30) . Therefore, the detection of resistance requires adaptation of the methods used for the efficient detection of these emerging resistance determinants.
In this study, we analyzed the distributions of MICs and inhibition zone diameters for both Salmonella and E. coli isolates separately to exclude the differences inherent in the susceptibility profiles of the two species and to observe the differences in resistance to the different quinolone compounds. We observed differences in drug potencies; the specificities toward substrates, for example, for isolates carrying aac(6Ј)Ibcr; and some differences in the phenotypes of isolates carrying the qnr determinants which might be related to their levels of expression of Qnr proteins. The differences observed seem to be related to the structural differences between the quinolones tested. Both quinolones and fluoroquinolones might be useful for the detection of the low-level resistance caused by these resistance determinants if the right breakpoints are set; so far, however, few data for other quinolone drugs are available (3, 19) . Nalidixic acid is known to be a very good drug for use for the detection of mutants; however, it would not be useful for the detection of isolates positive for qnr or aac(6Ј)Ib-cr mutations which might be found to have inhibition zones in the susceptible range. Some quinolone drugs such as oxolinic acid and flumequine showed good results for the detection of qnr genes along with mutations in those genes, whereas nalidixic acid was effective at distinguishing only strains harboring mutations. The fluoroquinolones tested showed good results for the detection of qnr genes with resistance determinants, but for aac(6Ј)Ib-cr, the best options would be either ciprofloxacin or norfloxacin, as expected due to the mechanism of resistance conferred by the enzymatic modification that is specific to these two drugs. However, although we advise the use of one of these drugs for optimization of the detection of strains carrying mutations in aac(6Ј)Ib-cr, they might still be undetected even when low breakpoints are used due to the low level of resistance conferred (23) .
In this study, both quantitative MIC determination and disk diffusion methods were used to test each of the quinolones. The results of the quantitative determination offer a much better ability to judge resistance levels, especially when strains carrying resistance determinants which confer only slight reductions in susceptibility are tested. For practical and economical reasons, many laboratories perform susceptibility testing by the disk diffusion assay, and therefore, we tried to observe if the inhibition zone diameter distributions obtained by the disk diffusion assay with a panel of quinolones could give some indications of the suitability of this method for the detection of the diverse quinolone resistance determinants. The results indicate, as is already known, that the disk diffusion test is good for the detection of target mutations, but only the results for ciprofloxacin or norfloxacin could be adapted to the detection of mutations in qnr and aac(6Ј)Ib-cr by the use of lower breakpoints (17, 23, 30) . Furthermore, the disk content presents another factor that must be considered. We observed that the use of a 1-g ciprofloxacin disk reduced the overlap between the results for susceptible strains and strains carrying transferable resistance compared to the results obtained with the traditionally used 5-g disk.
The results of this study are in agreement with previous knowledge on these resistance determinants, as mutations in qnr are known to protect the target the fluoroquinolones (24) (25) (26) 30) in general, and mutations in aac(6Ј)Ib-cr cause reductions in susceptibility to ciprofloxacin and norfloxacin. These are the only fluoroquinolones which possess the piperazynil amide side chain, which is acetylated by the enzyme encoded by aac(6Ј)Ib-cr (17, 23) . However, to our knowledge, similar studies have not been performed to optimize screening procedures in order to obtain increased sensitivity when strains that might contain such resistance determinants are selected.
In conclusion, according to the results obtained in this study, it is advisable that quantitative testing of susceptibility to either ciprofloxacin or norfloxacin be performed and that testing of susceptibility to nalidixic acid, which is a marker for target mutations, also be performed. However, if quantitative testing is not possible and disk diffusion is routinely carried out, a reduction in the inhibition zone diameter for fluoroquinolones and the observation of an inhibition zone for nalidixic VOL. 47, 2009 ACQUIRED QUINOLONE RESISTANCE DETERMINANT DETECTION 2757
on July 12, 2017 by guest http://jcm.asm.org/ acid might indicate the presence of transferable quinolone resistance, while the presence of mutations confers full resistance to nalidixic acid and no inhibition zone is observed.
